Retatrutide activates the glucagon receptor, and the glucagon receptor tells your liver to release sugar into your blood. In the trials, blood sugar still came down, and the reason is not that the glucagon receptor stopped working. It is that the same molecule pulls harder on the two receptors that clear sugar, and weight loss pulls with them.
This page settles the retatrutide blood sugar question that stops a lot of people cold once they understand what glucagon does. It covers how each of the three receptors moves glucose, what the phase 2 and phase 3 trials actually measured for fasting glucose and A1C, why a rising fasting glucose on retatrutide does not automatically point at the glucagon receptor, and what to watch on your own bloodwork. It is written for the researcher who has read that retatrutide burns more energy because of glucagon and then wondered what that does to blood sugar, whether or not they have diabetes.
Retatrutide pulls on both ends of the rope, and the clearing end usually wins
Picture a tug of war. On one end of the rope is glucagon, pulling to get your liver to release stored sugar into your blood. On the other end are GLP-1 and GIP, pulling to clear that sugar out, mostly by getting your pancreas to release insulin, the hormone that moves sugar from your blood into your muscles and liver. Your body runs this contest all day on its own. That is how blood sugar stays in a healthy range between meals and after them.
Retatrutide is one molecule that activates all three receptors, so it pulls on both ends of the rope at once. The question is which end pulls harder. In the published trials the clearing end won on average, which is why fasting glucose and A1C came down in people with obesity and in people with type 2 diabetes. The glucagon receptor did not lose its ability to raise blood sugar. It was outpulled, and eating less and losing weight added to the pull on the clearing side.
There is a second half to this that matters more for anyone reading their own labs. Based on the mechanism, if the dose is high enough or the ramp fast enough, the glucagon end could win for a stretch and fasting glucose could drift up. That is a reasonable thing to watch for. But the published research has not shown a specific retatrutide dose where fasting glucose rises across a trial group, so a mechanism that could happen is not the same as a result that did happen. Fasting glucose also moves with sleep, stress, what you ate the night before, other medications, and how well your body responds to insulin. A reading that went up does not prove the glucagon receptor is the reason.
If the question in your head right now is whether your own fasting glucose going up on retatrutide means the glucagon receptor is winning, ask it here and the first answer shows in full for free.
What glucagon does when nothing else is pulling on it
Glucagon is a hormone your pancreas makes on its own, from a different group of cells than the ones that make insulin. One of its main jobs is keeping your blood sugar from dropping too low, because when it drops too low you feel it right away. You get shaky, sweaty, and lightheaded. Your liver stores sugar during the day in a packed form called glycogen, which is just stored glucose. When you go several hours without eating, your body still needs fuel, so glucagon tells the liver to break that store down and release sugar into your blood. It also tells the liver to make new sugar from other raw material, a process called gluconeogenesis, which means building glucose from scratch.
That is the part everyone remembers about glucagon, and it is why the idea of activating the glucagon receptor on purpose sounds backwards at first. For years the research direction in diabetes was the opposite: block the glucagon receptor so the liver releases less sugar. Including glucagon activation in a weight loss compound only makes sense once you look at the other things the receptor does.
The glucagon receptor also sits on liver cells that control how the liver handles fat. Activating it increases how much energy the body burns and pushes the liver toward burning fat for fuel, which is a big part of why researchers are interested in retatrutide for liver fat and for total energy output, not just appetite. Semaglutide activates GLP-1. Tirzepatide activates GLP-1 and GIP. Retatrutide adds glucagon as the third, and the glucagon piece is what separates it from the two compounds before it. The full three receptor breakdown is covered in Retatrutide Explained: GLP-1 + GIP + Glucagon, so this page stays on the blood sugar question.
The catch is that you do not get to pick which part of the glucagon receptor you want. The fat burning and the sugar release come from the same receptor. You cannot have one without at least some of the other.
Glucose, fasting glucose, and insulin in plain English
Three terms carry the rest of this page. Glucose is the sugar in your blood, and it is what most of your body uses for energy. When anyone says blood sugar, glucose is what they mean. Fasting glucose is your blood sugar measured before you have eaten, usually first thing in the morning after about eight hours without food. People watch that number because nothing you just ate is affecting it, so it shows what your body is doing on its own. When fasting glucose stays high for months or years, that is usually how type 2 diabetes develops. A related number, A1C, is a blood test that reflects what your average blood sugar has been doing over roughly the last two to three months, because it measures how much sugar has attached to the hemoglobin in your red blood cells.
Insulin is the hormone your pancreas releases when sugar comes into your blood. It is the signal that moves sugar out of your blood and into your muscles and liver, where it gets used or stored. So insulin brings blood sugar down and glucagon brings it up. Those two work against each other all day, and that push and pull is how your body keeps blood sugar in range without you thinking about it.
How each receptor moves blood sugar
| Receptor | What it does to blood sugar | Which end of the rope |
|---|---|---|
| GLP-1 | When blood sugar is high, helps the pancreas release insulin. Slows how fast food leaves the stomach, especially early on. Lowers how much of your own glucagon gets released when blood sugar is already high. | Clearing |
| GIP | When blood sugar is high, helps the pancreas release insulin. When blood sugar is low, research suggests it can encourage the body to release some of its own glucagon. | Clearing when sugar is high, switches toward raising when sugar is low |
| Glucagon | Tells the liver to release stored sugar and make new sugar. Also increases energy burn and pushes the liver toward burning fat. | Raising |
GLP-1: the first clearing receptor
GLP-1 is the receptor every GLP-1 compound shares, and it does three things that matter for blood sugar. When glucose is high it helps the pancreas release insulin, and the important detail is that this effect is glucose dependent, meaning it mostly fires when sugar is already elevated and eases off when sugar is normal. That is a large part of why GLP-1 compounds on their own carry a low risk of pushing blood sugar too low. GLP-1 also slows gastric emptying, which is how fast food leaves your stomach, so sugar from a meal enters the blood more gradually. And it quiets your own glucagon release when blood sugar is high, which takes some pull off the raising end of the rope.
GIP: the receptor that changes sides
GIP is the receptor people tend to underestimate. When blood sugar is high, GIP helps release insulin just like GLP-1 does. But research suggests that when blood sugar is low, GIP can encourage the pancreas to release some of its own glucagon. In other words GIP is not on the clearing end under every condition. It shifts depending on where your blood sugar sits, and that shift is part of how the body keeps itself from dropping too low. This matters for retatrutide because the compound is strongest at this receptor, which is covered next.
Glucagon: the raising receptor that also burns fuel
The glucagon receptor does what the earlier section described. It raises blood sugar through the liver, and it raises energy burn through the liver too. On retatrutide those two effects come as a package. Based on the mechanism alone, the sugar release side is the one that could show up on a fasting glucose reading, since the liver's early morning sugar release is already the main thing a fasting number captures.
Retatrutide is not three separate compounds
Retatrutide is one molecule hitting three receptors, so you cannot turn up the glucagon end without also turning up GLP-1 and GIP. Raising the dose raises all three together. That does not mean all three respond with the same strength, though. In the published lab data, compared to the body's own hormones, retatrutide was several times stronger at the GIP receptor, roughly eight to nine fold in the reported assays, and weaker than the body's own hormone at both GLP-1 and glucagon.
| Receptor | Retatrutide strength versus the body's own hormone (lab data) | What that suggests |
|---|---|---|
| GIP | Several times stronger | The clearing receptor that also switches sides gets the strongest pull |
| GLP-1 | Weaker than native GLP-1 | Still clears, but with less force than a dedicated GLP-1 compound at the same receptor |
| Glucagon | Weaker than native glucagon | The raising receptor is the least strongly activated of the three |
Those numbers come from lab tests on cells, not from people. Receptor strength in a dish does not tell you which end of the rope wins in a human body, because the body responds to all three signals at once, with its own hormones, its own insulin sensitivity, and its own weight change layered on top. The lab data points toward the clearing end having the advantage. Only trials can confirm it.
Fasting glucose and A1C came down in people with and without diabetes
| Trial | Population | Blood sugar result | Status |
|---|---|---|---|
| Phase 2 obesity trial (published 2023) | Adults with obesity, no diabetes | Fasting glucose and A1C improved on average. Among those who started with prediabetes, about 72 percent on retatrutide had a normal A1C by week 48, compared to about 22 percent on placebo. | Peer reviewed |
| Phase 2 type 2 diabetes trial (published 2023) | Adults with type 2 diabetes | A1C dropped at the higher doses by roughly two percentage points at 36 weeks, with a large share reaching an A1C under 6.5 percent. | Peer reviewed |
| Phase 3 type 2 diabetes trial, first readout (2026) | Adults with type 2 diabetes | Average A1C drops of about 1.7 to 2.0 percentage points over 40 weeks, compared to about 0.8 on placebo. Fasting glucose was also measured and reported as improved. | Company reported top line |
| Pooled analysis of randomized trials (2025) | Mixed obesity trial populations | Fasting glucose fell by roughly 23 mg/dL and A1C by roughly 0.9 percentage points on average versus placebo across the included trials. | Peer reviewed meta analysis |
Two things stand out in that table. The first is that the direction is the same in every row. Whether the participants had diabetes or not, and whether the result was peer reviewed or company reported, blood sugar went down on average with the glucagon receptor turned on. The phase 3 numbers are still company reported and should be read that way until the full paper is out, but they point the same direction as the published research. The headline weight numbers from the phase 3 obesity program are a separate question from the blood sugar one and are not what this table is tracking.
The second thing is what the trials cannot tell you. An average across a group hides the spread inside it. A result that improves on average still leaves room for individuals whose fasting glucose did not move or moved the other way, and the published data does not break that down in a way a researcher can apply to one person. The glucagon receptor did not stop raising blood sugar in these people. The clearing end pulled harder, with eating less and losing weight pulling alongside it, and the average landed on the clearing side.
Why a rising fasting glucose on retatrutide does not prove the glucagon receptor is the cause
Here is where people get themselves into trouble reading their own bloodwork. Say someone is losing weight on retatrutide, but their fasting glucose has gone up over the last several weeks. Does that mean the glucagon end of the rope is winning? Not automatically. It is one possibility, but a fasting reading by itself does not prove it, because fasting glucose is one of the noisier numbers on a standard panel.
Fasting glucose moves with how much you slept, your stress level, what you ate the night before, and the sugar your liver normally releases in the early morning hours, which is sometimes called the dawn effect. Other medications can move it. So can a change in how well your body responds to insulin, which is worth taking seriously on its own. A single morning reading that came in higher than the last one can be any of those before it is the compound, and two readings a few weeks apart are still a short series.
The same logic applies to raising the dose. More retatrutide means more of the whole molecule, not more glucagon on its own. The glucagon end could win if the dose is high or the ramp is fast, and that comes from the mechanism, so it is worth paying attention to. But the published research has not identified a specific retatrutide dose where fasting glucose rises across a trial group. A mechanism tells you what might happen. A trial tells you what did happen in the people studied. Anyone deciding whether to move the dose at all is working through the questions in the Dose Escalation Decision Guide before blood sugar even enters it.
The consequence of skipping those steps is simple. The man who blames the glucagon receptor first is the man who either drops a compound that was working for a reason that was never the compound, or keeps pushing a dose while a real insulin problem sits underneath the reading and never gets looked at. Either way he is acting on one noisy number instead of the picture.
A fasting glucose reading on retatrutide only means something next to the markers that explain it, and most people never test fasting insulin or A1C alongside it. This tool takes your age, goal, and symptoms and returns the exact panel to bring to your doctor, with the blood sugar and metabolic markers ranked by what matters first. Three minutes now instead of weeks of guessing at one number.
Show Me My PanelFree. No login. Takes about three minutes.
The markers that read blood sugar on retatrutide better than the scale does
| Marker | What it shows | How to read it on retatrutide |
|---|---|---|
| Fasting glucose | Blood sugar after about eight hours without food, one morning at a time | Useful as a series, not as a single reading. One high number is noise until it repeats. A series that keeps climbing over several checks, especially into an abnormal range, is a doctor conversation, not a sign the compound is working. |
| A1C | Average blood sugar over roughly the last two to three months | The longer view. Smooths out sleep, stress, and last night's dinner. In the trials this is the number that moved most consistently. |
| Fasting insulin | How much insulin the pancreas is putting out to hold fasting glucose where it is | The number most people skip. A normal fasting glucose held up by a high fasting insulin is a different situation than a normal glucose with normal insulin, and the glucagon receptor is not the explanation for either. |
| Weight and waist | Whether the compound is doing its primary job | Losing weight pulls on the clearing end of the rope. A reader losing weight with a drifting fasting glucose has two signals pointing different ways, which is exactly when the other markers earn their place. |
Together, fasting glucose and A1C tell you more about what retatrutide is doing to your blood sugar than the scale does, and fasting insulin tells you whether the reading is being held in place by effort. A researcher who wants the baseline version of these markers before a compound ever enters the picture will find the three that most often sit behind a stall in Why You Can't Lose Weight: 3 Blood Markers Behind a Stall.
Back to the question
How does retatrutide turn on a receptor that raises blood sugar and still bring blood sugar down overall? Because it pulls on both ends of the rope at once, and in the trials the clearing end, along with eating less and losing weight, typically won. That does not make the glucagon receptor harmless, and it does not mean every person's blood sugar will respond the same way. It means you cannot look at one receptor by itself and assume you know what the whole compound is going to do, and you cannot look at one fasting reading by itself and assume you know which receptor is responsible.
Retatrutide and blood sugar FAQ
If you still have a question this page did not settle, something like whether retatrutide can cause low blood sugar when it is combined with another diabetes medication, type it into the Research Engine and the first answer shows in full for free.
For research and educational purposes only. Not medical advice. Compounds are discussed to explain how the body works, not as recommendations. Consult a licensed medical provider before making any decision about your health.